Based on this finding, a phase II trial was conducted for patients with endocrine-resistant ER+/HER2-low BC that had progressed after cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) therapy. The gene discussed is CDK4; the disease is breast cancer.